Two new RHD alleles with deletions spanning multiple exons.


Journal

Transfusion
ISSN: 1537-2995
Titre abrégé: Transfusion
Pays: United States
ID NLM: 0417360

Informations de publication

Date de publication:
03 2021
Historique:
revised: 29 09 2020
received: 19 08 2020
accepted: 11 10 2020
pubmed: 27 11 2020
medline: 15 7 2021
entrez: 26 11 2020
Statut: ppublish

Résumé

The most common large-deletion RHD allele (RHD*01N.01) includes the entire coding sequence, intervening regions and untranslated regions. The rest of large-deletion RHD alleles reported to-date consist of single-exon deletions, such as RHD*01N.67 which includes exon 1. Samples from two donors with RhD-negative serology yielded unclear or inconclusive results when subject to confirmatory testing on RHD genotyping arrays. To determine their RHD genotypes, genomic DNA was analyzed with a combination of allele-specific PCR, long-range PCR, Sanger sequencing, and next-generation sequencing assays. Allele-specific PCR failed to detect products for RHD exons 1 to 3 in one sample and RHD exons 1 to 5 in the other. A quantitative next-generation sequencing assay confirmed deletion of exons 1 to 3 and 1 to 5 respectively, and detected the absence of an RHD gene in trans in both samples. Long-range PCR and Sanger sequencing enabled identification of the breakpoints for both alleles. Both deletions start within the 5' Rhesus box (upstream of the identity region for the 1-to-3 deletion, downstream of it for the 1-to-5 deletion), and end within introns. Resolution of unclear or inconclusive results from targeted genotyping arrays often leads to the discovery of new alleles. The 5' Rhesus box may be a hot spot for genetic recombination events, such as the large deletions described in this report.

Sections du résumé

BACKGROUND
The most common large-deletion RHD allele (RHD*01N.01) includes the entire coding sequence, intervening regions and untranslated regions. The rest of large-deletion RHD alleles reported to-date consist of single-exon deletions, such as RHD*01N.67 which includes exon 1.
MATERIALS AND METHODS
Samples from two donors with RhD-negative serology yielded unclear or inconclusive results when subject to confirmatory testing on RHD genotyping arrays. To determine their RHD genotypes, genomic DNA was analyzed with a combination of allele-specific PCR, long-range PCR, Sanger sequencing, and next-generation sequencing assays.
RESULTS
Allele-specific PCR failed to detect products for RHD exons 1 to 3 in one sample and RHD exons 1 to 5 in the other. A quantitative next-generation sequencing assay confirmed deletion of exons 1 to 3 and 1 to 5 respectively, and detected the absence of an RHD gene in trans in both samples. Long-range PCR and Sanger sequencing enabled identification of the breakpoints for both alleles. Both deletions start within the 5' Rhesus box (upstream of the identity region for the 1-to-3 deletion, downstream of it for the 1-to-5 deletion), and end within introns.
CONCLUSIONS
Resolution of unclear or inconclusive results from targeted genotyping arrays often leads to the discovery of new alleles. The 5' Rhesus box may be a hot spot for genetic recombination events, such as the large deletions described in this report.

Identifiants

pubmed: 33241598
doi: 10.1111/trf.16199
doi:

Substances chimiques

Rh-Hr Blood-Group System 0
Rho(D) antigen 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

682-686

Informations de copyright

© 2020 AABB.

Références

Srivastava K, Stiles DA, Wagner FF, Flegel WA. Two large deletions extending beyond either end of the RHD gene and their red cell phenotypes. J Hum Genet. 2008;63:27-35.
Stegmann TC, Veldhuisen B, Bijman R, et al. Frequency and characterization of known and novel RHD variant alleles in 37 782 Dutch D-negative pregnant women. Br J Haematol. 2016;173:469-479.
Gowland P, Gassner C, Hustinx H, et al. Molecular RHD screening of RhD negative donors can replace standard serological testing for RhD negative donors. Transfus Apher Sci. 2014;50:163-168.
Hyland CA, Millard GM, O'Brien H, et al. Non-invasive fetal RHD genotyping for RhD negative women stratified into RHD gene deletion or variant groups: Comparative accuracy using two blood collection tube types. Pathology. 2017;49:757-764.
Richard M, Perreault J, Constanzo-Yanez J, Khalifé S, St-Louis M. A new DEL variant caused by exon 8 deletion. Transfusion. 2007;47:852-857.
Lopez GH, Turner RM, McGowan EC, et al. A DEL phenotype attributed to RHD exon 9 sequence deletion: Slipped-strand mispairing and blood group polymorphisms. Transfusion. 2018;58:685-691.
Fichou Y, Chen J-M, Le Maréchal C, et al. Weak D caused by a founder deletion in the RHD gene. Transfusion. 2012;52:2348-2355.

Auteurs

Antonella Matteocci (A)

Transfusion Medicine Unit, San Camillo Forlanini Hospital, Rome, Italy.

Jorge Monge-Ruiz (J)

Osakidetza, Basque Center for Blood Transfusion and Human Tissues, Galdakao, Spain.
Biocruces Bizkaia Health Research Institute, Cell Therapy, Stem Cells and Tissues Group, Barakaldo, Spain.

Marianne Stef (M)

Grifols Immunohematology Center, San Marcos, Texas, USA.

Izaskun Apraiz (I)

Progenika-Biopharma, Derio, Spain.

Lara Herrera-Del-Val (L)

Osakidetza, Basque Center for Blood Transfusion and Human Tissues, Galdakao, Spain.
Biocruces Bizkaia Health Research Institute, Cell Therapy, Stem Cells and Tissues Group, Barakaldo, Spain.

Tommaso Mancuso (T)

Immucor Italia S.p.A., Milan, Italy.

Katie Fennell (K)

Grifols Immunohematology Center, San Marcos, Texas, USA.

Monica Lopez (M)

Progenika-Biopharma, Derio, Spain.

Yolanda Larizgoitia-Martin (Y)

Osakidetza, Basque Center for Blood Transfusion and Human Tissues, Galdakao, Spain.

Guido Nespoli (G)

Transfusion Medicine Unit, San Camillo Forlanini Hospital, Rome, Italy.

Montserrat Rubia-Tejero (M)

Osakidetza, Basque Center for Blood Transfusion and Human Tissues, Galdakao, Spain.

Angela Collaretti (A)

Transfusion Medicine Unit, San Camillo Forlanini Hospital, Rome, Italy.

Luca Pierelli (L)

Transfusion Medicine Unit, San Camillo Forlanini Hospital, Rome, Italy.
Department of Experimental Medicine, Sapienza University, Rome, Italy.

Gorka Ochoa-Garay (G)

Grifols Immunohematology Center, San Marcos, Texas, USA.

Articles similaires

Genome, Chloroplast Phylogeny Genetic Markers Base Composition High-Throughput Nucleotide Sequencing

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C

Classifications MeSH